KA
CRDL

Kovack Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Kovack Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42K Buy
+30,000
New +$30.8K ﹤0.01% 997

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kovack Advisors's CRDL Position: Q1 2026 in Review

Kovack Advisors opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 30,000 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #997 among its holdings.

47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Kovack Advisors held 30,000 shares of Cardiol Therapeutics worth $42K as of Q1 2026.
  • Cardiol Therapeutics was a new Kovack Advisors position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Kovack Advisors's portfolio in Q1 2026, its #997 holding.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.